MDT

96.24

+0.35%↑

VEEV

285.71

-0.58%↓

A

138.04

-0.83%↓

HQY

94.48

+2.41%↑

PHR.US

22.63

+2.72%↑

MDT

96.24

+0.35%↑

VEEV

285.71

-0.58%↓

A

138.04

-0.83%↓

HQY

94.48

+2.41%↑

PHR.US

22.63

+2.72%↑

MDT

96.24

+0.35%↑

VEEV

285.71

-0.58%↓

A

138.04

-0.83%↓

HQY

94.48

+2.41%↑

PHR.US

22.63

+2.72%↑

MDT

96.24

+0.35%↑

VEEV

285.71

-0.58%↓

A

138.04

-0.83%↓

HQY

94.48

+2.41%↑

PHR.US

22.63

+2.72%↑

MDT

96.24

+0.35%↑

VEEV

285.71

-0.58%↓

A

138.04

-0.83%↓

HQY

94.48

+2.41%↑

PHR.US

22.63

+2.72%↑

Search

Pliant Therapeutics Inc

Отворен

1.52 4.11

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.45

Максимум

1.54

Ключови измерители

By Trading Economics

Приходи

13M

-43M

Марж на печалбата

-2,190.837

Служители

171

EBITDA

17M

-42M

Препоръки

By TipRanks

Препоръки

Неутрален

12-месечна прогноза

+79.87% upside

Дивиденти

By Dow Jones

Следващи печалби

6.11.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-13M

91M

Предишно отваряне

-2.59

Предишно затваряне

1.52

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

Pliant Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

13.10.2025 г., 21:45 ч. UTC

Придобивния, сливания и поглъщания

Goldman Sachs to Acquire Industry Ventures for Up to $965 Million -- Update

13.10.2025 г., 21:07 ч. UTC

Придобивния, сливания и поглъщания

Goldman Sachs to Acquire Industry Ventures for Up to $965 Million

13.10.2025 г., 17:03 ч. UTC

Значими двигатели на пазара

Canaan ADRs Climb on Launch of Gas-to-Computing Pilot in Canada

13.10.2025 г., 23:53 ч. UTC

Пазарно говорене

Gold Rises, Buoyed by Bullish Fundamental Backdrop -- Market Talk

13.10.2025 г., 23:39 ч. UTC

Пазарно говорене

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

13.10.2025 г., 22:15 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

13.10.2025 г., 22:15 ч. UTC

Пазарно говорене

Precinct Properties NZ's Equity Raising Looks Opportunistic -- Market Talk

13.10.2025 г., 21:57 ч. UTC

Придобивния, сливания и поглъщания

Goldman Buys $7B Venture-Capital Firm in Latest Asset-Management Bet -- Barrons.com

13.10.2025 г., 21:36 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

13.10.2025 г., 21:36 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

13.10.2025 г., 21:36 ч. UTC

Пазарно говорене

Fletcher's Near-Term Headwinds Don't Cloud Earnings Opportunity -- Market Talk

13.10.2025 г., 21:30 ч. UTC

Придобивния, сливания и поглъщания

Goldman Sachs to Acquire Industry Ventures for Up to $965M -- Update

13.10.2025 г., 21:06 ч. UTC

Придобивния, сливания и поглъщания

Goldman Buys $7B Venture-Capital Firm in Latest Asset-Management Bet -- Barrons.com

13.10.2025 г., 20:52 ч. UTC

Придобивния, сливания и поглъщания

Goldman Sachs to Acquire Industry Ventures for Up to $965M

13.10.2025 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

13.10.2025 г., 20:35 ч. UTC

Придобивния, сливания и поглъщания

Goldman Expects to Close Deal in 1Q

13.10.2025 г., 20:34 ч. UTC

Придобивния, сливания и поглъщания

Industry Ventures Will Be Part of Goldman's External Manager Platform, External Investing Group

13.10.2025 г., 20:33 ч. UTC

Придобивния, сливания и поглъщания

Industry Ventures Currently Manages $7B of Assets Under Supervision

13.10.2025 г., 20:32 ч. UTC

Придобивния, сливания и поглъщания

Goldman Sachs: Deal to Include Up to $300M of Additional Contingent Consideration Based on Future Performance Through 2030

13.10.2025 г., 20:31 ч. UTC

Придобивния, сливания и поглъщания

Goldman Sachs: Consideration to Include $665M Cash and Equity Payable at Closing

13.10.2025 г., 20:29 ч. UTC

Придобивния, сливания и поглъщания

Goldman Sachs to Buy VC Firm Industry Ventures

13.10.2025 г., 19:05 ч. UTC

Пазарно говорене

Oil Futures Pick Up on Easing U.S.-China Tension -- Market Talk

13.10.2025 г., 18:59 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

13.10.2025 г., 18:26 ч. UTC

Пазарно говорене

Precious Metals Close at New Record Highs -- Market Talk

13.10.2025 г., 18:10 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

13.10.2025 г., 18:10 ч. UTC

Пазарно говорене

Broadcom's OpenAI Deal Highlights AI Opportunity -- Market Talk

13.10.2025 г., 17:05 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

13.10.2025 г., 17:05 ч. UTC

Пазарно говорене

OpenAI Deal Offers Huge Upside to Broadcom's Earnings -- Market Talk

13.10.2025 г., 16:03 ч. UTC

Придобивния, сливания и поглъщания

Umicore Completes Sale, Subsequent Lease-in of Permanent Gold Inventories

13.10.2025 г., 15:35 ч. UTC

Пазарно говорене

Precious Metals Push Record Highs Further -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Pliant Therapeutics Inc Прогноза

Ценова цел

By TipRanks

79.87% нагоре

12-месечна прогноза

Среден 2.68 USD  79.87%

Висок 4 USD

Нисък 1.7 USD

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за Pliant Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

7 ratings

1

Купи

5

Задържане

1

Продай

Техническа оценка

By Trading Central

1.43 / 1.6Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Средносрочен план

Bearish Evidence

Дългосрочен план

Weak Bearish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
help-icon Live chat